07 | MD Anderson Cancer Center Skip to Content
Top

BY Clayton Boldt, Ph.D.

Mutations in the ARID1a gene, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. But this mutated gene may also strengthen specific cancer drugs’ ability to treat certain tumors, according to a team of MD Anderson researchers.

Their study, published in Cancer Discovery, discovered that certain mutations in ARID1a sensitize some tumors to PARP inhibitor drugs, such...

BY MD Anderson staff

It’s the Friday before Father’s Day, and V. Craig Jordan, Ph.D., who’s considered the “Father of Tamoxifen,” is sitting down to talk about...

BY Clayton Boldt, Ph.D.

The costs associated with cancer drug prices have risen dramatically over the past fifteen years, which concerns many top oncologists. In...

BY Laura Sussman

The first national review of breast-conserving therapy (BCT) shows that over the last 13 years, rates of this treatment for early-stage breast cancer have increased at a steady pace. However, the review also highlights demographic factors that impact whether or not a patient will have access to BCT. MD Anderson researchers found that disparities related to age, treatment facility type and geographic region, are declining. But they also...

BY Laura Sussman

Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic...

BY MD Anderson staff

The Supreme Court’s recent ruling on same-sex marriage has cleared the way for MD Anderson Cancer Center to offer some long-awaited benefits...

BY Ron Gilmore

MD Anderson researchers believe they may have found a way to detect pancreatic cancer at an early stage, before it has spread to other organs...

BY Scott Merville

A molecule expressed by the Epstein-Barr virus is found in the B cells, bone marrow and plasma of patients with chronic lymphocytic leukemia...